Patents by Inventor Friedrich Scheiflinger

Friedrich Scheiflinger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION THERAPY OF ANTI-MIF ANTIBODIES AND GLUCOCORTICOIDS
    Publication number: 20180280501
    Abstract: The present invention pertains to anti-MIF antibodies, in particular their use in combination with glucocorticoids, in the treatment of glucocorticoid receptive diseases.
    Type: Application
    Filed: November 1, 2017
    Publication date: October 4, 2018
    Inventors: Randolf Kerschbaumer, Dirk Voelkel, Friedrich Scheiflinger, Hartmut Ehrlich
  • TFPI INHIBITORS AND METHODS OF USE
    Publication number: 20180155399
    Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. Peptide complexes also are provided. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound.
    Type: Application
    Filed: November 16, 2017
    Publication date: June 7, 2018
    Applicants: Baxalta GmbH, Baxalta Incorporated
    Inventors: Michael DOCKAL, Rudolf HARTMANN, Friedrich SCHEIFLINGER, Frank OSTERKAMP, Thomas POLAKOWSKI, Ulrich REINEKE
  • OxMIF as a diagnostic marker
    Patent number: 9958456
    Abstract: The present invention pertains to the recognition that a specific oxMIF form of MIF is useful as a diagnostic marker in (MIF-related) diseases, in particular for example monitoring of disease progression. The present invention also pertains to the respective use of a diagnostic kit and a respective diagnostic assay and pertains to advantageous respective antibodies.
    Type: Grant
    Filed: October 4, 2012
    Date of Patent: May 1, 2018
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Michael Thiele, Randolf J. Kerschbaumer, Dirk Voelkel, Patrice Douillard, Friedrich Scheiflinger
  • COMPOSITIONS COMPRISING ADAMTS13 FOR USE IN METHODS FOR THE RECANALIZATION OF OCCLUDED BLOOD VESSELS IN AN INFARCTION
    Publication number: 20180110842
    Abstract: Provided herein are methods for recanalization of occluded blood vessels in a subject having an infarction. The method includes a step of administering to the subject a therapeutically effective amount of isolated ADAMTS13 protein at particular dosages and ranges of times after detection of the infarction. As described herein, ADAMTS13 advantageously recanalizes occluded blood vessels and reduces infarction size, even when administered a prolonged period after stable occlusion. Accordingly, such methods and compositions are useful for the treatment of infractions caused by blood vessel occlusion.
    Type: Application
    Filed: May 26, 2016
    Publication date: April 26, 2018
    Applicants: Baxalta Incorporated, Baxalta GmbH, Katholieke Universiteit Leuven
    Inventors: Barbara PLAIMAUER, Hanspeter ROTTENSTEINER, Friedrich SCHEIFLINGER, Simon DE MEYER, Frederik DENORME
  • TFPI INHIBITORS AND METHODS OF USE
    Publication number: 20180072784
    Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, and/or treat a blood coagulation disorder in a subject.
    Type: Application
    Filed: August 18, 2017
    Publication date: March 15, 2018
    Applicants: Baxalta GmbH, Baxalta Incorporated
    Inventors: Michael DOCKAL, Hartmut Ehrlich, Friedrich Scheiflinger, Ulf Reimer, Ulrich Reineke, Thomas Polakowski, Eberhard Schneider
  • TFPI inhibitors and methods of use
    Patent number: 9873720
    Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. Peptide complexes also are provided. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound.
    Type: Grant
    Filed: December 29, 2014
    Date of Patent: January 23, 2018
    Assignees: Baxalta GmbH, Baxalta Incorporated
    Inventors: Michael Dockal, Rudolf Hartmann, Friedrich Scheiflinger, Frank Osterkamp, Thomas Polakowski, Ulrich Reineke
  • TFPI inhibitors and methods of use
    Patent number: 9777051
    Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, and/or treat a blood coagulation disorder in a subject.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: October 3, 2017
    Assignees: Baxalta GmbH, Baxalta Incorporated
    Inventors: Michael Dockal, Hartmut Ehrlich, Friedrich Scheiflinger, Ulf Reimer, Ulrich Reineke, Thomas Polakowski, Eberhard Schneider
  • VIRAL VECTORS ENCODING RECOMBINANT FVIII VARIANTS WITH INCREASED EXPRESSION FOR GENE THERAPY OF HEMOPHILIA A
    Publication number: 20170233455
    Abstract: The present disclosure provides, among other aspects, codon-altered polynucleotides encoding Factor VIII variants for expression in mammalian cells. In some embodiments, the disclosure also provides mammalian gene therapy vectors and methods for treating hemophilia A.
    Type: Application
    Filed: November 11, 2016
    Publication date: August 17, 2017
    Inventors: Falko-Günter Falkner, Franziska Horling, Johannes Lengler, Hanspeter Rottensteiner, Friedrich Scheiflinger
  • VIRAL VECTORS ENCODING RECOMBINANT FVIII VARIANTS WITH INCREASED EXPRESSION FOR GENE THERAPY OF HEMOPHILIA A
    Publication number: 20170226188
    Abstract: The present disclosure provides, among other aspects, codon-altered polynucleotides encoding Factor VIII variants for expression in mammalian cells. In some embodiments, the disclosure also provides mammalian gene therapy vectors and methods for treating hemophilia A.
    Type: Application
    Filed: November 11, 2016
    Publication date: August 10, 2017
    Inventors: Falko-Günter Falkner, Franziska Horling, Johannes Lengler, Hanspeter Rottensteiner, Friedrich Scheiflinger
  • RECOMBINANT CO-EXPRESSION OF VITAMIN K EPOXIDE REDUCTASE SUBUNIT 1 TO IMPROVE VITAMIN K DEPENDENT PROTEIN EXPRESSION
    Publication number: 20170226487
    Abstract: The present invention relates to a host organism containing recombinant nucleic acids coding for the vitamin K reductase complex subunit 1 (VKORC1) and recombinant nucleic acids coding for a vitamin K dependent (VKD) protein, wherein both the recombinant VKORC1 and the recombinant VKD protein are expressed in said host organism. Further, the present invention relates to a cell culture system comprising cells which contain said recombinant nucleic acids and to methods for improving the productivity of recombinant VKD protein expression in a host organism being cultured in suitable systems.
    Type: Application
    Filed: January 18, 2017
    Publication date: August 10, 2017
    Applicants: Baxalta GmbH, Baxalta Incorporated
    Inventors: Friedrich Scheiflinger, Ernst Boehm
  • BIOLOGICALLY ACTIVE PEPTIDES
    Publication number: 20170174724
    Abstract: A peptide or peptide derivative comprising: (i) WDLYFEIVW (SEQ ID NO: 1); or (ii) a variant amino acid sequence comprising one, two, three or four L-amino acid substitutions in WDLYFEIVW (SEQ ID NO: 1); or (iii) the retro-inverso variant of the peptide or peptide derivative of either one of parts (i) and (ii), wherein said peptide or peptide derivative has procoagulant activity. A peptide or peptide derivative comprising: (i) an amino acid sequence comprising imfwydcye; or (ii) a variant amino acid sequence comprising one, two, three, four, five or six amino acid substitutions in imfwydcye, wherein said peptide or peptide derivative has procoagulant activity.
    Type: Application
    Filed: February 27, 2017
    Publication date: June 22, 2017
    Inventors: Friedrich Scheiflinger, Michael Dockal
  • TFPI INHIBITORS AND METHODS OF USE
    Publication number: 20170174727
    Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. Peptide complexes also are provided. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound.
    Type: Application
    Filed: December 29, 2014
    Publication date: June 22, 2017
    Applicants: BAXALTA GMBH, BAXALTA INCORPORATED
    Inventors: MICHAEL DOCKAL, RUDOLF HARTMANN, FRIEDRICH SCHEIFLINGER, FRANK OSTERKAMP, THOMAS POLAKOWSKI, ULRICH REINEKE
  • TFPI INHIBITORS AND METHODS OF USE
    Publication number: 20170157198
    Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, an identify a TFPI-binding compound.
    Type: Application
    Filed: December 9, 2016
    Publication date: June 8, 2017
    Applicants: BAXALTA GMBH, BAXALTA INCORPORATED
    Inventors: Michael Dockal, Rudolf Hartmann, Markus Fries, Friedrich Scheiflinger, Hartmut Ehrlich, Ulrich Reineke, Frank Osterkamp, Thomas Polakowski
  • Nucleic acids encoding vitamin K expoxide reductase subunit 1 and vitamin K dependent protein expression and methods of using same
    Patent number: 9617523
    Abstract: The present invention relates to a host organism containing recombinant nucleic acids coding for the vitamin K reductase complex subunit 1 (VKORC1) and recombinant nucleic acids coding for a vitamin K dependent (VKD) protein, wherein both the recombinant VKORC1 and the recombinant VKD protein are expressed in said host organism. Further, the present invention relates to a cell culture system comprising cells which contain said recombinant nucleic acids and to methods for improving the productivity of recombinant VKD protein expression in a host organism being cultured in suitable systems.
    Type: Grant
    Filed: January 27, 2006
    Date of Patent: April 11, 2017
    Assignees: Baxalta GmbH, Baxalta Incorporated
    Inventors: Friedrich Scheiflinger, Ernst Boehm
  • Biologically active peptides
    Patent number: 9598464
    Abstract: The invention provides a method of making a peptide or peptide derivative comprising the amino acid sequence comprising imfwydcye or a variant amino acid sequence comprising one, two, three, four, five or six amino acid substitutions in imfwydcye.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: March 21, 2017
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Friedrich Scheiflinger, Michael Dockal
  • Composition Exhibiting a von Willebrand Factor (vWF) Protease Activity Comprising a Polypeptide Chain with the Amino Acid Sequence AAGGILHLELLV
    Publication number: 20170065686
    Abstract: The invention relates to vWF cleaving entities having a molecular weight of 180 kD, 170 kD, 160 kD, 120 kD or 110 kD and an N-terminal amino acid sequence of AAGGILHLELLV, vWF cleaving complexes and methods for their production.
    Type: Application
    Filed: April 8, 2016
    Publication date: March 9, 2017
    Inventors: Bernhard Laemmle, Helena Elisabeth Schaller-Gerritsen, Miha Furlan, Peter Turecek, Hans-Peter Schwarz, Friedrich Scheiflinger, Gerhard Antoine, Randolf Kerschbaumer, Luigina Tagliavacca, Klaus Zimmermann
  • COMBINATION THERAPY OF ANTI-MIF ANTIBODIES AND CHEMOTHERAPEUTICS
    Publication number: 20170049885
    Abstract: The present invention pertains to anti-MIF antibodies, in particular their use in combination with cancer therapeutics, i.e. chemotherapeutics, in the treatment of cancer.
    Type: Application
    Filed: June 6, 2016
    Publication date: February 23, 2017
    Inventors: Randolf Kerschbaumer, Friedrich Scheiflinger, Hartmut Ehrlich
  • Preparations based on fibrinogen and sulfated polysaccharides
    Patent number: 9566364
    Abstract: The present invention provides a preparation comprising fibrinogen and a sulfated polysaccharide as a one component composition or as a kit of parts comprising fibrinogen and sulfated polysaccharide as separated components. The present invention further provides a fibrin clot like structure obtainable by a defined process, a hemostatic patch, a two-component syringe system and various uses of the described preparations, fibrin clot like structures and patches.
    Type: Grant
    Filed: December 11, 2009
    Date of Patent: February 14, 2017
    Assignees: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A.
    Inventors: Michael Dockal, Friedrich Scheiflinger, Hans Christian Hedrich, Klaus Tschetschkowitsch, Andreas Goppelt
  • PEPTIDES AND METHODS OF USE
    Publication number: 20170035835
    Abstract: The invention provides peptides, including peptides that bind and, optionally, inhibit Protein S, and compositions thereof. The peptides may be used to, e.g., inhibit Protein S activity, enhance thrombin formation in a subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify Protein S, and identify a Protein S binding compound.
    Type: Application
    Filed: August 19, 2016
    Publication date: February 9, 2017
    Inventors: Michael Dockal, Thomas Polakowski, Frank Osterkamp, Rudolf Hartmann, Matthias Paschke, Bettina Hartlieb, Friedrich Scheiflinger
  • TFPI inhibitors and methods of use
    Patent number: 9556230
    Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: January 31, 2017
    Assignees: BAXALTA GMBH, BAXALTA INCORPORATED
    Inventors: Michael Dockal, Rudolf Hartmann, Markus Fries, Friedrich Scheiflinger, Hartmut Ehrlich, Ulrich Reineke, Frank Osterkamp, Thomas Polakowski